Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: A pilot study comparing pre- and post-operative levels

Molecular Genetics and Metabolism

Volumn 89, Issue 4, 2006, Pages 381-389

  Klug, T L ^a   Bageman E ^b   Ingvar, C ^b   Rose, C ^c   Jernstrom H ^b  

^a Immuna Care Corporation   (United States)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

16 Hydroxyestrone; 2 Hydroxyestrogen; Alcohol; Breast cancer; Coffee; CYP1A2; Polymorphism; Prognosis; Radiotherapy; Tamoxifen

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTROGEN; CYTOCHROME P450 1A2; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ALCOHOL CONSUMPTION; ALLELE; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COFFEE; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADJUVANTS, PHARMACEUTIC; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; BREAST NEOPLASMS; COFFEE; CYTOCHROME P-450 CYP1A2; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; HYDROXYESTRONES; HYDROXYTESTOSTERONES; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE PERIOD; RECEPTORS, ESTROGEN; TAMOXIFEN;

JOINVILLEA ASCENDENS;

EID: 33750631277     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.08.005     Document Type: Article

References (50)

1. Schneider J., Huh M.M., Bradlow H.L., and Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem. 259 (1984) 4840-4845
2. Telang N.T., Suto A., Wong G.Y., Osborne M.P., and Bradlow H.L. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst. 84 (1992) 634-638
3. Kabat G.C., Chang C.J., Sparano J.A., Sepkovic D.W., Hu X.P., Khalil A., Rosenblatt R., and Bradlow H.L. Urinary estrogen metabolites and breast cancer: a case-control study [see comments]. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 505-509
4. Ho G.H., Luo X.W., Ji C.Y., Foo S.C., and Ng E.H. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann. Acad. Med. Singapore 27 (1998) 294-299
5. Meilahn E.N., De Stavola B., Allen D.S., Fentiman I., Bradlow H.L., Sepkovic D.W., and Kuller L.H. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br. J. Cancer 78 (1998) 1250-1255
6. Muti P., Bradlow H.L., Micheli A., Krogh V., Freudenheim J.L., Schunemann H.J., Stanulla M., Yang J., Sepkovic D.W., Trevisan M., and Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women [In Process Citation]. Epidemiology 11 (2000) 635-640
7. Ursin G., London S., Stanczyk F.Z., Gentzschein E., Paganini-Hill A., Ross R.K., and Pike M.C. A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ. Health Perspect. 105 (1997) 601-605
8. Ursin G., London S., Stanczyk F.Z., Gentzschein E., Paganini-Hill A., Ross R.K., and Pike M.C. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 91 (1999) 1067-1072
9. Cauley J.A., Zmuda J.M., Danielson M.E., Ljung B.M., Bauer D.C., Cummings S.R., and Kuller L.H. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 14 (2003) 740-744
10. Wellejus A., Olsen A., Tjonneland A., Thomsen B.L., Overvad K., and Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2137-2142
11. Modugno F., Kip K.E., Cochrane B., Kuller L., Klug T.L., Rohan T.E., Chlebowski R.T., Lasser N., and Stefanick M.L. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int. J. Cancer 118 (2006) 1292-1301
12. Fowke J.H., Qi D., Bradlow H.L., Shu X.O., Gao Y.T., Cheng J.R., Jin F., and Zheng W. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 68 (2003) 65-72
13. W. Zheng, L. Dunning, F. Jin, J. Holtzman, Correspondence re: G.C. Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study, Cancer Epidemiol. Biomarkers Prev. 6 (1997) 505-509; Cancer Epidemiol. Biomarkers Prev. 7 (1998) 85-86.
14. Bradlow H.L., and Sepkovic D.W. Diet and breast cancer. Ann. N.Y. Acad. Sci. 963 (2002) 247-267
15. Michnovicz J.J., Hershcopf R.J., Naganuma H., Bradlow H.L., and Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N. Engl. J. Med. 315 (1986) 1305-1309
16. Lurie G., Maskarinec G., Kaaks R., Stanczyk F.Z., and Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1521-1527
17. Hong C.C., Tang B.K., Hammond G.L., Tritchler D., Yaffe M., and Boyd N.F. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 6 (2004) R352-R365
18. Hong C.C., Tang B.K., Rao V., Agarwal S., Martin L., Tritchler D., Yaffe M., and Boyd N.F. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res. 6 (2004) R338-R351
19. Parkinson A. Biotransformation of Xenobiotics. fifth ed. (1996), McGraw-Hill Inc., Kansas City, KS pp. 113-186
20. Sachse C., Brockmoller J., Bauer S., and Roots I. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47 (1999) 445-449
21. Le Marchand L., Donlon T., Kolonel L.N., Henderson B.E., and Wilkens L.R. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1998-2003
22. Mikhailova O.N., Gulyaeva L.F., Prudnikov A.V., Gerasimov A.V., and Krasilnikov S.E. Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J. (2006) 189-193
23. Goodman M.T., Tung K.H., McDuffie K., Wilkens L.R., and Donlon T.A. Association of caffeine intake and CYP1A2 genotype with ovarian cancer. Nutr. Cancer 46 (2003) 23-29
24. Klug T.L., Bradlow H.L., and Sepkovic D.W. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16-alpha-hydroxyestrone in urine. Steroids 59 (1994) 648-655
25. Ziegler R.G., Rossi S.C., Fears T.R., Bradlow H.L., Adlercreutz H., Sepkovic D., Kiuru P., Wahala K., Vaught J.B., Donaldson J.L., Falk R.T., Fillmore C.M., Siiteri P.K., Hoover R.N., and Gail M.H. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Environ. Health Perspect. 105 Suppl. 3 (1997) 607-614
26. Bradlow H.L., Sepkovic D.W., Klug T., and Osborne M.P. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 63 (1998) 406-413
27. Falk R.T., Rossi S.C., Fears T.R., Sepkovic D.W., Migella A., Adlercreutz H., Donaldson J., Bradlow H.L., and Ziegler R.G. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 81-87
28. Jernström H., Klug T.L., Sepkovic D.W., Bradlow H.L., and Narod S.A. Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis 24 (2003) 991-1005
29. Westerlind K.C., Gibson K.J., and Wolfe P. The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease-risk assessment. Steroids 64 (1999) 233-243
30. Bradlow H.L., Jernstrom H., Sepkovic D.W., Klug T.L., and Narod S.A. Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16alpha-hydroxyestrogen metabolites. Mol. Genet. Metab. 87 (2006) 135-146
31. Liehr J.G., and Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. USA 93 (1996) 3294-3296
32. Emons G., Ball P., and Knuppen R. Radioimmunoassays of catechol estrogens. In: Merriam G.R., and Lipsett M.B. (Eds). Catecholestrogens (1983), Raven, New York 151-165
33. Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M., and Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7 (1997) 391-396
34. Lee A.J., Cai M.X., Thomas P.E., Conney A.H., and Zhu B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144 (2003) 3382-3398
35. Strombeck J.O., and Malm M. Priority grouping in a waiting list of patients for reduction mammaplasty. Ann. Plast. Surg. 17 (1986) 498-502
36. Imoto S., Mitani F., Enomoto K., Fujiwara K., Ikeda T., Kitajima M., and Ishimura Y. Influence of estrogen metabolism on proliferation of human breast cancer. Breast Cancer Res. Treat. 42 (1997) 57-64
37. Jefcoate C.R., Liehr J.G., Santen R.J., Sutter T.R., Yager J.D., Yue W., Santner S.J., Tekmal R., Demers L., Pauley R., Naftolin F., Mor G., and Berstein L. Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Monogr. (2000) 95-112
38. Castagnetta L.A., Granata O.M., Traina A., Ravazzolo B., Amoroso M., Miele M., Bellavia V., Agostara B., and Carruba G. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin. Cancer Res. 8 (2002) 3146-3155
39. Wazer D.E., Tercilla O.F., Lin P.S., and Schmidt-Ullrich R. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br. J. Radiol. 62 (1989) 1079-1083
40. Paulsen G.H., Strickert T., Marthinsen A.B., and Lundgren S. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol. 35 (1996) 1011-1019
41. Sarkaria J.N., Miller E.M., Parker C.J., Jordan V.C., and Mulcahy R.T. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res. Treat. 30 (1994) 159-165
42. Ellis P.A., Saccani-Jotti G., Clarke R., Johnston S.R., Anderson E., Howell A., A'Hern R., Salter J., Detre S., Nicholson R., Robertson J., Smith I.E., and Dowsett M. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int. J. Cancer 72 (1997) 608-613
43. Recht A., Come S.E., Henderson I.C., Gelman R.S., Silver B., Hayes D.F., Shulman L.N., and Harris J.R. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N. Engl. J. Med. 334 (1996) 1356-1361
44. Ahn P.H., Vu H.T., Lannin D., Obedian E., DiGiovanna M.P., Burtness B., and Haffty B.G. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J. Clin. Oncol. 23 (2005) 17-23
45. Pierce L.J., Hutchins L.F., Green S.R., Lew D.L., Gralow J.R., Livingston R.B., Osborne C.K., and Albain K.S. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J. Clin. Oncol. 23 (2005) 24-29
46. Harris E.E., Christensen V.J., Hwang W.T., Fox K., and Solin L.J. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J. Clin. Oncol. 23 (2005) 11-16
47. Bentzen S.M., and Yarnold J.R. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see-that is the question!. J. Clin. Oncol. 23 (2005) 6266-6267 (author reply 6267)
48. Essmann F., Engels I.H., Totzke G., Schulze-Osthoff K., and Janicke R.U. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res. 64 (2004) 7065-7072
49. Nkondjock A., Ghadirian P., Kotsopoulos J., Lubinski J., Lynch H., Kim-Sing C., Horsman D., Rosen B., Isaacs C., Weber B., Foulkes W., Ainsworth P., Tung N., Eisen A., Friedman E., Eng C., Sun P., and Narod S.A. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 118 (2006) 103-107
50. Hamajima N., Hirose K., Tajima K., Rohan T., Calle E.E., Heath Jr. C.W., Coates R.J., Liff J.M., Talamini R., Chantarakul N., Koetsawang S., Rachawat D., Morabia A., Schuman L., Stewart W., Szklo M., Bain C., Schofield F., Siskind V., Band P., Coldman A.J., Gallagher R.P., Hislop T.G., Yang P., Kolonel L.M., Nomura A.M., Hu J., Johnson K.C., Mao Y., De Sanjose S., Lee N., Marchbanks P., Ory H.W., Peterson H.B., Wilson H.G., Wingo P.A., Ebeling K., Kunde D., Nishan P., Hopper J.L., Colditz G., Gajalanski V., Martin N., Pardthaisong T., Silpisornkosol S., Theetranont C., Boosiri B., Chutivongse S., Jimakorn P., Virutamasen P., Wongsrichanalai C., Ewertz M., Adami H.O., Bergkvist L., Magnusson C., Persson I., Chang-Claude J., Paul C., Skegg D.C., Spears G.F., Boyle P., Evstifeeva T., Daling J.R., Hutchinson W.B., Malone K., Noonan E.A., Stanford J.L., Thomas D.B., Weiss N.S., White E., Andrieu N., Bremond A., Clavel F., Gairard B., Lansac J., Piana L., Renaud R., Izquierdo A., Viladiu P., Cuevas H.R., Ontiveros P., Palet A., Salazar S.B., Aristizabel N., Cuadros A., Tryggvadottir L., Tulinius H., Bachelot A., Le M.G., Peto J., Franceschi S., Lubin F., Modan B., Ron E., Wax Y., Friedman G.D., Hiatt R.A., Levi F., Bishop T., Kosmelj K., Primic-Zakelj M., Ravnihar B., Stare J., Beeson W.L., Fraser G., Bullbrook R.D., Cuzick J., Duffy S.W., Fentiman I.S., Hayward J.L., Wang D.Y., McMichael A.J., McPherson K., Hanson R.L., Leske M.C., Mahoney M.C., Nasca P.C., Varma A.O., Weinstein A.L., Moller T.R., Olsson H., Ranstam J., Goldbohm R.A., van den Brandt P.A., Apelo R.A., Baens J., de la Cruz J.R., Javier B., Lacaya L.B., Ngelangel C.A., La Vecchia C., Negri E., Marubini E., Ferraroni M., Gerber M., Richardson S., Segala C., Gatei D., Kenya P., Kungu A., Mati J.G., Brinton L.A., Hoover R., Schairer C., Spirtas R., Lee H.P., Rookus M.A., van Leeuwen F.E., Schoenberg J.A., McCredie M., Gammon M.D., Clarke E.A., Jones L., Neil A., Vessey M., Yeates D., Appleby P., Banks E., Beral V., Bull D., Crossley B., Goodill A., Green J., Hermon C., Key T., Langston N., Lewis C., Reeves G., Collins R., Doll R., Peto R., Mabuchi K., Preston D., Hannaford P., Kay C., Rosero-Bixby L., Gao Y.T., Jin F., Yuan J.M., Wei H.Y., Yun T., Zhiheng C., Berry G., Cooper Booth J., Jelihovsky T., MacLennan R., Shearman R., Wang Q.S., Baines C.J., Miller A.B., Wall C., Lund E., Stalsberg H., Shu X.O., Zheng W., Katsouyanni K., Trichopoulou A., Trichopoulos D., Dabancens A., Martinez L., Molina R., Salas O., Alexander F.E., Anderson K., Folsom A.R., Hulka B.S., Bernstein L., Enger S., Haile R.W., Paganini-Hill A., Pike M.C., Ross R.K., Ursin G., Yu M.C., Longnecker M.P., Newcomb P., Kalache A., Farley T.M., Holck S., and Meirik O. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br. J. Cancer 87 (2002) 1234-1245